Search

for
Search:

Did you mean Janus Kinase 1?

GlossaryJanus Kinase 1

enzyme involved in immune signaling and cell growth

Janus Kinase 1 (JAK1) is an enzyme that plays a crucial role in the signaling pathways of various cytokines, which are proteins important for immune system communication. It is part of the JAK family of tyrosine kinases and is involved in processes such as cell growth, development, and immune responses. In the context of hair and alopecia, JAK1 inhibitors are being researched as potential treatments for conditions like alopecia areata, an autoimmune disorder that causes hair loss.

Related Terms

Sort by

Research

30 / 1000+ results

Selective Janus Kinase 1 Inhibition Resolves Inflammation and Restores Hair Growth Offering a Viable Treatment Option for Alopecia Areata

research Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata

4 citations , January 2023 in “Skin health and disease”

Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.

research Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing

34 citations , June 2020 in “British journal of dermatology/British journal of dermatology, Supplement”

Frontal fibrosing alopecia is linked to increased immune system activity and reduced stem cells, suggesting early treatment targeting this pathway might prevent hair follicle damage.

research Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry

September 2025 in “Chinese Journal of Chromatography”

A new method accurately detects illegal JAK inhibitors in hair loss cosmetics.

Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients

research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients

24 citations , January 2018 in “International Journal of Trichology”

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients

48 citations , November 2017 in “Journal of the American Academy of Dermatology”

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Effectiveness and Safety of Oral Janus Kinase Inhibitors in Patients Aged 12 or Younger With Alopecia Areata: A Systematic Review and Meta-Analysis

research Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis

March 2026 in “Mendeley Data”

Janus kinase inhibitors help hair regrowth in kids with alopecia areata but need more safety research.

research Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis

March 2026 in “Mendeley Data”

Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.

research 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells

April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology”

JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.

Efficacy and Adverse Effects of Oral Janus Kinase Inhibitor Use in Patients With Lichen Planopilaris: A Retrospective Case Series and Systematic Review

research 151 Efficacy and adverse effects of oral Janus kinase inhibitor (JAKi) use in patients with lichen planopilaris: a retrospective case series and systematic review

November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology”

Oral Janus kinase inhibitors may be an effective treatment option for lichen planopilaris with some risk of increased cholesterol and liver enzyme levels.

research The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus

7 citations , March 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial

2 citations , November 2025 in “Journal of the American Academy of Dermatology”

Off-Label Use of Biologics and Janus Kinase Inhibitors for Scarring Alopecias: A Narrative Review

research Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review

3 citations , June 2025 in “Archives of Dermatological Research”

Biologics and JAK inhibitors may improve treatment for scarring alopecias.

research Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience

March 2026 in “Immunological Medicine”

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

research Ann Robinson’s research reviews —12 May 2022

May 2022 in “The BMJ”

Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.

research 013 IL-15/IL-15Rα signaling is a guardian of human hair follicle immune privilege and promotes hair growth

November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology”

IL-15 promotes hair growth and protects hair follicles.

research JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician

6 citations , October 2024 in “Journal of Family Medicine and Primary Care”

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

research Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older

December 2025 in “Actas Dermo-Sifiliográficas”

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata

23 citations , October 2024 in “British Journal of Dermatology”

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

research Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data

September 2023 in “Dermatology and Therapy”

Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.

Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2

research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2

September 2023 in “Journal of The American Academy of Dermatology”

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.

research Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses

59 citations , September 2021 in “Journal of Allergy and Clinical Immunology”

Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.

research Alopecia areata following COVID-19 vaccine: a systematic review

8 citations , July 2024 in “European journal of medical research”

Alopecia areata after COVID-19 vaccination is rare but important to recognize for timely treatment.

research Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata

4 citations , April 2024 in “Journal of Drugs in Dermatology”

Ruxolitinib cream may help treat severe hair loss in children.

research 1313 Fzd2 controls multiple aspects of epidermal development through distinct signaling mechanisms

1 citations , April 2018 in “Journal of Investigative Dermatology”

Fzd2 is important for skin and hair development through various signaling ways.

research Iron Chelators in the Management of Autoimmune-Induced Alopecia: A Focus on Hypoxia-Inducible Factor 1 Modulation and Hair Restoration

March 2025 in “Journal of Clinical Medicine”

Iron chelators can effectively reduce hair loss and improve hair growth in autoimmune alopecia.

research Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute

June 2025 in “The Journal of Dermatology”

Baricitinib is effective and safe for long-term treatment of severe alopecia areata.

Search

for
Search:

Related Terms

Research

research Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata

research Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing

research Determination of 13 janus kinase inhibitors in anti-alopecia cosmetics by ultra-high performance liquid chromatography-tandem triple quadrupole composite linear ion trap mass spectrometry

research Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A promising therapy for the treatment of alopecia areata: A case report of six patients

research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients

research Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis

research Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis

research 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells

research 151 Efficacy and adverse effects of oral Janus kinase inhibitor (JAKi) use in patients with lichen planopilaris: a retrospective case series and systematic review

research The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus

research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial

research Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review

research Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience

research Ann Robinson’s research reviews —12 May 2022

research 013 IL-15/IL-15Rα signaling is a guardian of human hair follicle immune privilege and promotes hair growth

research JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician

research Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older

research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata

research Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data

research 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2

research Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses

research Alopecia areata following COVID-19 vaccine: a systematic review

research Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata

research 1313 Fzd2 controls multiple aspects of epidermal development through distinct signaling mechanisms

research Iron Chelators in the Management of Autoimmune-Induced Alopecia: A Focus on Hypoxia-Inducible Factor 1 Modulation and Hair Restoration

research Alopecia universalis with IL-12-RB1 and STAT4 mutations effectively treated with upadacitinib

research Reply to early onset effluvium secondary to COVID-19 and body-hair effluvium

research Prenatal diagnosis of a foetus with partial monosomy 4p and partial trisomy 13q

research Therapeutic Approaches for Alopecia Areata in Children Aged 6 to 11 Years

research Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute